The First 48 Consecutive Patients with 3-Year Symptom Score Follow-Up Post-Prostate Artery Embolization (PAE) at a Single-Centre University Hospital
Few studies on prostate artery embolization (PAE) follow patients up after 12 months. We aimed to evaluate the symptomatic efficacy of PAE in our patient cohort at 3 years.
A total of 48 consecutive patients undergoing PAE from June 2012 to August 2014 were included in this retrospective study. All patients underwent formal urodynamics to confirm bladder outflow obstruction prior to PAE. International Prostate Symptom Score (IPSS) was performed at baseline, 3 months, 12 months and 3 years post-PAE.
Mean patient age was 65.6 ± 7.4, prostate volume 99.1 ± 56.6 cm3, IPSS 23.5 ± 6.0, quality-of-life score 4.6 ± 0.9, Qmax 8.4 ± 2.8 ml/s, post-void residual volume 185.8 ± 55.6 ml. Technical success (bilateral embolization) was achieved in 43 out of 48 cases (89.6%). 11/39 bilateral PAE patients completing follow-up (2 died, 2 lost to follow-up) underwent surgery, indicating a 71.2% clinical success rate at 3 years. No significant change was demonstrated in IPSS or QOL between 1 and 3 years for patients free from surgical intervention (IPSS 8.3 vs 10.0, p = 0.09 and QOL 1.3 vs 1.5, p = 0.23). 3/11 patients undergoing surgery had a prominent ‘ball-valve’ median lobe, and 1/11 patients had a high bladder neck elevation contributing to symptoms.
Clinical success post-PAE remains high with few patients opting for surgery or experiencing a worsening of symptoms after 12 months.
KeywordsProstate PAE Embolization Clinical Mid-term BPH
This study was not supported by any funding.
Compliance with Ethical Standards
Conflict of interest
Nigel Hacking has received honoraria from Boston Scientific and Celonova as a speaker and has been on Advisory boards for BTG. Tim Bryant has proctored for Boston Scientific and Terumo and has received speaker honorariums from Boston Scientific. Sachin Modi has received a speaker honorarium from Boston Scientific. The other authors declare no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
Consent for Publication
Consent for publication was obtained for every individual person’s data included in the study.
- 1.Carnevale FC, Iscaife A, Yoshinaga EM, Moreira AM, Antunes AA, Srougi M. Transurethral Resection of the prostate (TURP) versus original and PErFecTED Prostate artery embolization (PAE) due to benign prostatic hyperplasia (BPH): preliminary results of a single center, prospective, urodynamic-controlled analysis. Cardiovasc Intervent Radiol. 2016;39(1):44–52.CrossRefGoogle Scholar
- 2.Abt D, Hechelhammer L, Müllhaupt G, Markart S, Güsewell S, Kessler TM, et al. Comparison of prostatic artery embolisation (PAE) versus transurethral resection of the prostate (TURP) for benign prostatic hyperplasia: randomised, open label, non-inferiority trial. BMJ. 2018;361:k2338.CrossRefGoogle Scholar
- 7.Zumstein V, Betschart P, Vetterlein MW, Kluth LA, Hechelhammer L, Mordasini L, et al. Prostatic artery embolization versus standard surgical treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis. Eur Urol Focus. 2018. https://doi.org/10.1016/j.euf.2018.09.005.CrossRefPubMedGoogle Scholar
- 10.Assis AM de, de Assis AM, Moreira AM, de Paula Rodrigues VC, Yoshinaga EM, Antunes AA, et al. Prostatic ARTERY EMBOLIZATION FOR TREATMENT OF BENIGN prostatic hyperplasia in patients with prostates %3e 90 g: a prospective single-center study. J Vascular Intervent Radiol. 2015. 26: 87–93.https://dx.doi.org/10.1016/j.jvir.2014.10.012
- 11.Wang MQ, Guo LP, Zhang GD, Yuan K, Li K, Duan F, et al. Prostatic arterial embolization for the treatment of lower urinary tract symptoms due to large (%3e80 mL) benign prostatic hyperplasia: results of midterm follow-up from Chinese population. BMC Urol. 2015. https://doi.org/10.1186/s12894-015-0026-5.CrossRefPubMedPubMedCentralGoogle Scholar
- 18.Yu SCH, Cho CCM, Hung EHY, Zou J, Yuen BTY, Shi L, et al. Thickness-to-height ratio of intravesical prostatic protrusion predicts the clinical outcome and morbidity of prostatic artery embolization for benign prostatic hyperplasia. J Vasc Intervent Radiol. 2019. https://doi.org/10.1016/j.jvir.2019.07.035.CrossRefGoogle Scholar